Jun 19, 2019 - Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
Sep 05, 2019 - Investors need to be careful about which pharmaceutical stocks they own.
Sep 05, 2019 - Endo (ENDP) receives an FDA approval for the generic equivalent of Swedish Orphan Biovitrum's Orfadin.
Sep 06, 2019 - Rising investments and growing technological advancement are favoring the genomic editing space. We take a look at a few ETFs that can cash in on this trend.
Sep 11, 2019 - The FDA is expected to give its decision on Allergan's (AGN) BLA for its anti-VEGF product, abicipar pegol in mid-2020, while the EMA's decision is expected in the second half of 2020.
Sep 13, 2019 - Glaxo's (GSK) Nucala gets FDA nod for use in kids. Pfizer (PFE), Allergan (AGN) & Roche (RHHBY) give regular pipeline/regulatory updates.
Jun 20, 2019 - Companies In The News Are:
Sep 06, 2019 - Allergan (AGN) settles with two Ohio plaintiffs for $5 million. Merck's (MRK) Keytruda, Roche's (RHHBY) Tecentriq and J&J's (JNJ) Stelara get EU approval for expanded use.
Sep 13, 2019 - Consumer groups and unions want the FTC to block AbbVie's (ABBV +0.4%) $63B acquisition of Allergan (AGN), according to a STAT report.The coalition says the increasingly concentrated nature of the hea
Sep 13, 2019 - Ardelyx (ARDX) gets first-ever FDA approval for its pipeline candidate, tenapanor, as a treatment for irritable bowel syndrome with constipation in adults. It will be available under the tradename Ibsrela.